Episode 153: Myeloma Capstone, Pt 2 - MRD-Guided Therapy, Maintenance, and Relapsed/Refractory Sequencing
About this episode
The episode discusses MRD-guided therapy, maintenance strategies, and sequencing for relapsed/refractory myeloma treatment with expert guests.
Therapy, Maintenance, and Relapsed/Refractory Sequencing This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part two, we cover three practical and rapidly evolving topics: the role of MRD testing in guiding treatment decisions, how to individualize maintenance therapy in 2026, and how to approach sequencing of CAR-T and bispecific therapies in the relapsed/refractory setting. In this week’s show notes, we summarize the key thoughts about how our experts think about approach to their patients. If you have not already done so, be sure to check out Part 1 of this discussion! Content: - What are the practical implications of MRD-testing in myeloma treatment? - How do we think about maintenance therapy in the present day? - What therapies are on the horizon? - How do we approach management of younger patients with relapsed/refractory disease? - How do we approach bridging therapy? ** This episode is sponsored by Primum! To learn…
People in this episode
Guests: Dr. Manni Mohyuddin, Dr. Adeel Khan
Topics covered
- myeloma treatment
- MRD testing
- maintenance therapy
- relapsed/refractory disease
- CAR-T therapy
- bispecific therapies
Keywords
- myeloma
- MRD testing
- maintenance therapy
- relapsed disease
- CAR-T
- bispecific therapies
- treatment decisions
Sponsors
Primum
Mentioned in this episode
Organizations: Huntsman Cancer Institute, University of Utah, UT Southwestern
More episodes of The Fellow on Call: The Heme/Onc Podcast
- Episode 157: Immune Thrombocytopenic Purpura Series, Pt 3- Challenging Scenarios in ITP
- Episode 156: Immune Thrombocytopenic Purpura Series, Pt 2- Relapsed/Refractory
- Episode 155: Immune Thrombocytopenic Purpura Series, Pt 1- First Line Management
- Episode 154: Ask The Program Directors-The Do’s and Don'ts of Applying to Hematology Fellowship (Career Development Series)
- Episode 152: Myeloma Capstone, Pt 1 - Smoldering Myeloma & Frontline Treatment in the Elderly
- Episode 151: Myeloma Series, Pt. 11 - Role of bispecific T-cell engagers for relapsed/refractory multiple myeloma (2026)
Explore listener stats, chart rankings, contacts and more on the The Fellow on Call: The Heme/Onc Podcast podcast page.